Business
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management Ca...
About this update from Bright Minds Biosciences Inc.
[{"type":"text","content":"\n \n \n \n Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO\n \n THE UNITED STATES\n \n /\n \n \n \n \n \n \n VANCOUVER, BC\n \n \n ,\n \n \n Dec. 6, 2023\n \n \n /CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (\"Bright Minds\" or the \"Company\"), a leading biotechnology company specializing in the development of novel treatments for neuropsychiatric disorders, epilepsy, and pain, is excited to announce a fully management-subscribed, non-brokered private placement. This placement involves up to 661,765 units of the Company (the \"Units\") at a price of\n \n $1.36\n \n per Unit, aiming for aggregate gross proceeds of up to\n \n $900,000\n \n (the \"Offering\").\n \n \n Each Unit in this Offering will consist of one common share in the capital of Bright Minds (a \"Share\") and one Share purchase warrant (a \"Warrant\"). Each Warrant grants the holder the right to acquire one Share (a \"Warrant Share\") at a price of\n \n $1.70\n \n per Warrant Share, valid for a period of 60 months following the Offering's closing date.\n \n \n This Offering is being conducted under the listed issuer financing exemption as per Part 5A of National Instrument 45-106 - Prospectus Exemptions. As a result, the securities issued will not be subjected to a hold period under the prevailing Canadian securities laws. An Offering Document related to this placement is available on the Company's SEDAR+ profile at\n \n www.sedarplus.ca\n \n and on\n \n https://brightmindsbio.com/\n \n . Potential investors are advised to thoroughly review this document prior to making any investment decisions.\n \n \n The proceeds from the Offering are intended to further the progress of Bright Minds' Phase 2 Clinical Trial for BMB-101 in a pediatric epilepsy indication. The exp...